Long‐term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial
After two additional years of follow-up, ripretinib showed a trend toward clinically meaningful OS benefit versus sunitinib in the Ex11 ITT population. Second-line ripretinib does not appear to affect third-line treatment efficacy.
Authors
- Ye Zhou (ORCID: https://orcid.org/0000-0002-9270-3322)
- Xin Wu (ORCID: https://orcid.org/0000-0002-8935-6075)
- Zhaolun Cai (ORCID: https://orcid.org/0000-0002-3706-6703)
- Ming Wang (ORCID: https://orcid.org/0000-0002-9977-7041)
- Peifa Liu
- Xingye Wu (ORCID: https://orcid.org/0000-0002-2265-7869)
- Yue Ma (ORCID: https://orcid.org/0000-0001-8115-5204)
- Jiayu Ling (ORCID: https://orcid.org/0000-0002-1376-6000)
- Kuntang Shen
- Xuelong Jiao (ORCID: https://orcid.org/0000-0002-0348-9732)
- Yingjiang Ye (ORCID: https://orcid.org/0000-0002-7904-3163)
- Haibo Qiu (ORCID: https://orcid.org/0000-0001-9360-6682)
- Bo Zhang (ORCID: https://orcid.org/0000-0002-0254-5843)
- Yong Li (ORCID: https://orcid.org/0000-0003-1799-4841)
- Zhuo Liu (ORCID: https://orcid.org/0000-0002-1137-7220)
- Xinhua Zhang (ORCID: https://orcid.org/0000-0002-3155-7114)
- Lei Cheng (ORCID: https://orcid.org/0000-0003-1311-515X)
- Jian Li (ORCID: https://orcid.org/0000-0002-9333-3255)
- Pengfei Zhang (ORCID: https://orcid.org/0000-0003-3470-085X)
- Yongjian Zhou (ORCID: https://orcid.org/0000-0002-3940-1595)
- Lin Shen (ORCID: https://orcid.org/0000-0003-4635-1108)
- Jun Zhang (ORCID: https://orcid.org/0000-0002-5843-8705)
- Yanbing Zhou (ORCID: https://orcid.org/0000-0002-1865-3064)
- Yuping Zhu (ORCID: https://orcid.org/0000-0001-5045-3380)
- Haijiang Wang (ORCID: https://orcid.org/0000-0002-7123-7983)
- Jiejie Jin (ORCID: https://orcid.org/0000-0002-7405-5229)
- Zhaojie An
- Hua‐Long Zheng (ORCID: https://orcid.org/0000-0002-2749-0113)
- Zhidong Gao (ORCID: https://orcid.org/0009-0002-8120-1420)
- Yanqiao Zhang
- Hongyan Qu
Institutions
- Qingdao University (CN)
- Hebei Medical University (CN)
- Fujian Medical University (CN)
- Xinjiang Medical University (CN)
- Harbin Medical University (CN)
- Sun Yat-sen University (CN)
- Shanghai Jiao Tong University (CN)
- Peking University (CN)
- Sichuan University (CN)
- Fudan University (CN)
- Renji Hospital (CN)
- Chinese PLA General Hospital (CN)
- West China Hospital of Sichuan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- Peking University Cancer Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Tumor Hospital of Xinjiang Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Peking University People's Hospital (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Wuhan Union Hospital (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
- Sun Yat-sen University Cancer Center (CN)
- Union Hospital (CN)
- University of Chinese Academy of Sciences (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/cncr.70150
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00